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Background: Chronic systemic inflammatory syndrome has been implicated in the pathobiology of extrapulmonary
manifestations of chronic obstructive pulmonary disease (COPD). We aimed to investigate which cell types within lung
tissue are responsible for expressing major acute-phase reactants in COPD patients and disease-free (“resistant”) smokers.
Methods: An observational case–control study was performed to investigate three different cell types in surgical lung
samples of COPD patients and resistant smokers via expression of the C-reactive protein (CRP) and serum amyloid A
(SAA1, SAA2 and SAA4) genes. Epithelial cells, macrophages and fibroblasts from the lung parenchyma were separated
by magnetic microbeads (CD326, CD14 and anti-fibroblast), and gene expression was evaluated by RT-PCR.
Results: The sample consisted of 74 subjects, including 40 COPD patients and 34 smokers without disease. All three
cell types were capable of synthesizing these biomarkers to some extent. In fibroblasts, gene expression analysis of the
studied biomarkers demonstrated increased SAA2 and decreased SAA1 in patients with COPD. In epithelial cells, there
was a marked increase in CRP, which was not observed in fibroblasts or macrophages. In macrophages, however, gene
expression of these markers was decreased in COPD patients compared to controls.
Conclusions: These results provide novel information regarding the gene expression of CRP and SAA in different cell
types in the lung parenchyma. This study revealed differences in the expression of these markers according to cell type
and disease status and contributes to the identification of cell types that are responsible for the secretion of these
molecules.
Keywords: Chronic obstructive pulmonary disease, Chronic systemic inflammatory syndrome, Acute-phase reactants,
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Chronic obstructive pulmonary disease (COPD) is associ-
ated with important extrapulmonary manifestations includ-
ing cardiovascular disease, weight loss, skeletal muscle
dysfunction, depression and osteoporosis [1]. Although
the pathobiology of these extra-pulmonary manifestations* Correspondence: ccalero-ibis@us.es
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unless otherwise stated.has not been fully determined, systemic inflammation
has been implicated in the pathogenesis of the majority
of these manifestations [2,3]. In fact, several authors
have suggested that COPD is part of a chronic systemic
inflammatory syndrome [4].
Patients with COPD display systemic inflammation,
measured either as increased circulating cytokines, che-
mokines and acute-phase proteins or as abnormalities in
circulating cells [5,6]. Acute-phase reactants are among
the most studied biomarkers. In particular, C-reactive
protein (CRP) is related to an accelerated decline in lungLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Calero et al. BMC Pulmonary Medicine 2014, 14:95 Page 2 of 9
http://www.biomedcentral.com/1471-2466/14/95function and many other clinically relevant outcomes
[7,8]. Serum amyloid A (SAA), the other major acute-phase
reactant in humans, has also been shown to be elevated
in COPD patients [9].
There has been considerable interest in identifying the
nature of COPD-mediated systemic inflammation, as such
knowledge may help predict clinical responses to therapy
and identify new therapeutic targets. One important issue
is identifying the origin of systemic inflammation, which
is currently controversial [10]. This would be a major
advancement, and doing so could have an important
diagnostic impact by identifying therapeutic targets to
prevent disease progression to other organs, thereby
preventing comorbidities [11]. The current hypothesis
holds that this inflammation is generated within the lung
and produces an overflow (referred to in the literature
as “spill-over”) of inflammatory mediators into the
bloodstream [12].
Previous studies have described how lung tissue can
synthesize acute-phase biomarkers in healthy tissue as
well as in animal or cell models [13]. Additionally, our
group has reported that, in addition to the liver, the lung
can also synthesize CRP and SAA. Interestingly, de-novo
synthesis of CRP and SAA is increased in patients with
COPD compared to disease-free smokers (“resistant
smokers”), and this synthesis is differentially expressed
in whole tissue samples depending on the anatomical
location, such as the bronchus or the parenchyma [14].
In the present study, we aimed to investigate the cell
types within lung tissue that express these biomarkers.
We hypothesized that the expression of acute-phase
reactants in lung tissue would differ with respect to the
cell type used and would vary between COPD patients
and healthy smokers. The objectives of this study were
to characterize the gene expression of CRP and SAA in
key lung cell types, including epithelial cells, macro-
phages and human lung fibroblasts, and to compare the




We recruited consecutive patients from the surgical wait-
ing list from February 2010 to June 2012 who were about
to undergo elective pneumonectomy or lobectomy for
suspected primary lung cancer. The study was approved
by the institutional review board at Hospital Virgen del
Rocío, and patients provided written informed consent
prior to being included in the study. Each patient was
identified upon his or her day of admission (i.e., the day
before surgery was planned). Patients who were under
40 years of age, had a history of acute respiratory infection
during the preceding 2 months, had been previously diag-
nosed with a neoplasm, had received radiotherapy orchemotherapy prior to the surgery or had suffered from
chronic inflammatory disease were excluded from the
study. Furthermore, time from the opening of the cutane-
ous layer to the extraction of the anatomical sample
was measured, and cases in which this time was greater
than 3 hours were also excluded from the study, as any
potential stimulation of the studied biomarkers due to
surgery could not be ruled out.
Medical records were checked to ensure that the
patients had recently been tested for lung function.
Patients whose pre-surgical spirometry results revealed
a forced expiratory volume in the first second (FEV1)/
forced vital capacity (FVC) ratio <0.7 were classified as
COPD, and the remaining resistant smokers were used
as control subjects. All patients completed a standardized
questionnaire regarding their medical history, tobacco
consumption and actual treatments. Comorbidities were
evaluated using the Charlson index [15]. Furthermore, the
TNM staging of the primary lesion [16] and information
regarding the surgical procedure were also collected.
During surgery, a portion of the lung parenchyma of
approximately 1 cm2 in area and 0.5 cm thick that was
grossly normal and distant from the injury that had
motivated the intervention was selected. This separation
was performed in the operating room, and the sample was
immediately placed in sterile surgical biopsy ice for preser-
vation. The rest of the surgical piece followed the usual
guidelines according to hospital protocol and the patient’s
clinical case. To exclude bronchial colonization that could
bias our results, analyses of microbiological colonization
were performed at two time points: first, during the bron-
choscopy that was performed to establish the diagnosis
and to study the extent of the primary lesion, and second,
prior to extraction of the tissue by obtaining an intrabron-
chial sample from the resected bronchus.
Laboratory techniques
The collected samples consisted of pulmonary parenchyma
tissues from each of the patients (COPD cases and con-
trols).To determine the gene expression levels of acute-
phase reactants in different cell types, we performed
cell disintegration of the fibroblasts, epithelial cells and
macrophages. Disintegration consisted of mechanical
grinding using a scalpel to achieve fragmentation and
treatment with enzymes in a digestion medium composed
of RPMI, 5% fetal bovine serum (FBS), 1% streptomycin/
penicillin,1% L-glutamine (all from PAA Laboratories,
Gmb, Germany), 0.1 mM 2-β-mercaptoethanol (Sigma,
GmbH, Germany), 1 mg/mL collagenase I (Sigma, GmbH,
Germany) and 0.02 mg/mL DNase I. The samples were
maintained in this medium at 37°C for 25 minutes and
were then neutralized with collagenase and DNase in
RPMI supplemented with 5% FBS, 1% streptomycin/
penicillin and 1% L-glutamine. Once neutralized, the






Males (n) 26 (76.5) 37 (92.5) NS
Age (years) 63.1 (10.7) 66.2 (7.6) NS
Tobacco history (pack-years) 48.8 (101.3) 51.5 (27.7) NS
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at 4°C. The supernatant was then removed, and the pel-
lets were washed with a solution of PBS/10 mM EDTA.
Next, the samples were filtered at 40 microns (Becton
Dickinson, NJ, USA) and were again centrifuged at
1000 rpm for 5 min at 4°C, followed by removal of the
supernatant. We performed erythrocyte lysis on the pellets
(Erythrocyte lysis buffer, QIAGEN, Gmb, Germany)
following the manufacturer’s protocol. Separation of the
different cell types was performed by binding cell-specific
antibodies to magnetic beads (MACS microbeads, Milte-
nyi Biotec, Bergisch Gladbach, Germany) according to the
manufacturer’s instructions. The selected markers were
CD326 (for epithelial cells), CD14 (for macrophages)
and anti-fibroblast (for fibroblasts). After incubating
the samples with the various antibodies, they were
passed through a magnetic separation column (MACS
MS column, Miltenyi Biotec, Bergisch Gladbach, Germany).
Then, the cells remaining in the columns were collected
(CD326+, CD14+ or fibroblasts), and RNA extraction was
performed using the TRIzol-chloroform method (TRIsur-
eTM, Bioline Ltd., United Kingdom). The RNA was treated
with RNase-free DNase using a commercial kit (QIAgen,
GmbH) to remove any residual genomic DNA, and cDNA
was synthesized using an iScript kit (Bio-Rad, CA).
Each reaction was duplicated at a total volume of 25 μL
and contained 2 μL cDNA (40 ng/μL) and 12.5 μL SYBR
Green. Cell purity was determined by flow cytometry in all
of the samples. The results indicated cell purity values
close to 90%, with no major differences among samples.
PCR master mix (Stratagene, CA) and 10.5 μL primers/
H2O were then used. RT-qPCR was performed using a
MX3005P system (Stratagene) at 95°C for 30 s, 60°C for
1 min and 72°C for 30 s. Gene amplification was nor-
malized to 18 s RNA expression. The primers used for
amplification are described in Table 1. Because human
SAA protein consists of 3 tightly linked genes (SAA1,
SAA2 and SAA4) [17], the GenBank database from the
National Center for Biotechnology Information (NCBI)
was consulted, and portions of the genes that were not
in the homology region were selected. These primers
were then synthesized ad hoc by an external company
(Sigma-Aldrich). Gene expression analysis was performed
following the 2-ΔCt method [18].Table 1 Primers used in this study
Forward Reverse




SAA4 5'-GTCCAACGAGAAAGCTGAGG-3' 5'-AGTGACCCTGTGTCCCTGTC-3'Statistical analysis
Statistical analysis was performed using the Statistical
Package for Social Sciences (SPSS), version 20.0 (IBM
Corporation, Somers, NY, USA). Absolute and relative
frequencies were used to describe qualitative variables.
Quantitative variables were expressed in terms of means
and standard deviations. The analysis of RFA expression
at the cellular level between COPD patients and resistant
smokers was performed using the Mann–Whitney U test.
Correlations were assessed using Spearman’s coefficient.
Logistic regression analysis was used to investigate whether
significant differences between the two study groups
persisted after adjustment for body mass index, age,
gender, FEV1 and the Charlson index. The accepted
alpha error was 0.05.
Results
Patients and procedures
The sample consisted of 74 subjects, including 40 COPD
patients and 34 disease-free smokers. The characteristics
of these patients are summarized in Table 2. The distri-
bution of patients according to their spirometric classifica-
tion per GOLD 2014 was as follows: 15 (37.5%) with mild
impairment (FEV1 = 88.3, 8.7%), 22 (55.0%) with moder-
ate impairment (FEV1 = 66.5, 7.6%), 2 (5.0%) with severe
impairment (FEV1 = 45.5, 2.1%), and 1 (2.5%) with very
severe impairment (FEV1 = 25%). Inhaled corticosteroids
were used to treat 12.8% of COPD patients. The mean
dose of inhaled corticosteroids in COPD patients was 750
(353) mg of fluticasone propionate or its equivalent
per day. The most frequent primary neoplasms were
adenocarcinomas (39.2%) and squamous cell carcinomas
(36.5%). Although all cases underwent operations for
suspected neoplasms, 8.1% of the patients had lesions
that were either histologically benign or had non-neoplastic
pathologies. The most frequent comorbidities, apart from
respiratory diseases and neoplasms, were diabetes (16Comorbidities (Charlson index) 2.6 (1.6) 3.9 (1.3) <0.001
BMI (kg/m2) 26.5 (4.5) 25.8 (7.07) NS
FVC (%) 90.6 (17.1) 93.1 (17.9) NS
FEV1 (%) 86.2 (16.5) 72.2 (16.4) 0.001
FEV1/FVC (%) 75.6 (6.3) 61.2 (8.8) < 0.001
The data are expressed as absolute (relative) frequencies or means (standard
deviations), as appropriate. *p values were calculated using Chi-square or
Mann–Whitney tests, as appropriate.
BMI: body mass index. FVC: forced vital capacity. FEV1: forced expiratory
volume in one second. NS: not significant.
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disease (7 patients) and liver disease (7 patients). Only
three cases had positive cultures either in the broncho-
scopic study or during the intervention: two in the
COPD group and one in the control group.
Expression of acute-phase reactants in epithelial cells,
macrophages and human lung fibroblasts
All three cell types were capable of synthesizing these
biomarkers to some extent. Gene expression was not
related to the presence of a neoplasm, the tumor type,
TNM staging, inhaled corticosteroid intake, degree of
lung function impairment in COPD or presence of a
positive microbiological culture. Depending on the cell
type studied, we found two different patterns. The CRP
and SAA1 genes were more strongly expressed in epi-
thelial cells (Figure 1a and b), whereas the SAA2 and
SAA4 genes were more strongly expressed in fibroblasts
(Figure 1c and d).
Within one cell type, the gene expression patterns of
these biomarkers were correlated. In fibroblasts, there
was a strong correlation between the SAA1 and SAA2
genes (r = 0.608, p < 0001). However, there was no evidence
of a correlation between SAA1 (r = 0.387, p = 0.001) or
SAA2 (r = 0.201, p = 0.086) and CRP. In epithelial cells,
the highest correlations were between the different0.069
0.001
Figure 1 Relative gene expression of a) C-reactive protein, b) serum am
to cell type.SAA genes (SAA1 vs. SAA2: r = 0.962, p < 0.001), with
weaker correlations between the SAA and CRP genes
(CRP and SAA1: r = 0.579, p < 0.001; CRP and SAA2:
r = 0.452, p < 0.001). However, in macrophages, the cor-
relations were uniformly low across all biomarkers,
with r values of approximately 0.4 and p values <0.001
for all comparisons.Gene expression of acute-phase reactants in these cell
groups between COPD patients and healthy smokers
When analyzing the gene expression of each biomarker,
we observed different patterns depending on the cell
type (Figures 2, 3 and 4). In fibroblasts, gene expression
of the studied biomarkers was increased in the COPD
cases, especially for SAA2 (Figure 2). Thus, gene expres-
sion increased for SAA2 and decreased for SAA1 in
COPD patients.
In epithelial cells, gene expression was also increased,
albeit the difference was less striking (Figure 3). In
epithelial cells, there was a striking increase in CRP,
which was not observed in fibroblasts or macrophages.
In macrophages, however, gene expression was decreased
in COPD patients compared to controls, particularly for
SAA1 and SAA2, with no change in CRP (Figure 4). The
results of multivariate analysis indicated that these results0.04 0.002
yloid A1, c) serum amyloid A2 and d) serum amyloid A4 according
Figure 2 Relative gene expression of acute-phase reactants in fibroblasts in COPD patients and controls.
Figure 3 Relative gene expression of acute-phase reactants in epithelial cells in COPD patients and controls.
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Figure 4 Relative gene expression of acute-phase reactants in macrophages in COPD patients and controls.
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confounders, including body mass index, age, gender,
FEV1 and the Charlson index.
Discussion
The present study provides novel information regarding
the expression of CRP and SAA in the lung parenchyma.
We identified differences in production according to the
cell type and the presence or absence of disease. The
results of the present study reflect two main findings:
firstly, all fibroblasts, epithelial cells and macrophages
express CRP and SAA, and secondly, expression of both
markers differs according to cell type and the presence
of disease.
To correctly interpret the results, several issues should
be considered. First, because all the study subjects were
admitted for a pulmonary resection (lobectomy or pneu-
monectomy) for suspected primary lung cancer and
therefore met the criteria for surgery, 92.3% of the
COPD patients had mildly or moderately impaired lung
function. Therefore, this was not representative of all
COPD patients because there were few surgical speci-
mens from patients with advanced-stage COPD. Second,
the resected neoplasms included several tumor types
and several non-neoplastic cases, and it is unclear whether
the observed changes were dependent on tumor type.
In the present study, histological types were adequatelydistributed with proportional numbers for each type of
neoplasm, and we found no influence of tumor type on
the results. Third, although the tissues analyzed were
not macroscopically affected by the tumors, it remains
unclear whether microscopic influences maybe involved.
Data from the diagnostic techniques and current high-
resolution images make this possibility very unlikely.
However, different genetic predispositions for COPD
cases with and without lung cancer have previously been
described [19]. Therefore, the results of our project should
be strictly applied to patients with COPD with similarly
located lung neoplasms. Fourth, because surgery itself can
potentially stimulate the studied biomarkers, cases for
which the time between the opening of the skin plane and
surgical excision exceeded 3 hours were excluded. The
described increase in reactants occurs several hours
following acute injury and remains elevated for several days
[20]. Therefore, three hours was considered a reasonable
time for such surgical procedures without complications.
Fifth, these results apply to the lung parenchyma. This
implies that fibroblasts, macrophages and epithelial
cells are obtained, in the best case, in the terminal
bronchi and the lung parenchyma. In this regard, the
roles of these cells may be more relevant to heavier
gauged airways [21]. In contrast, the expected effect
of COPD on the parenchyma would be emphysema,
which would result from an imbalance between various
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equilibrium [22], protease-antiprotease equilibrium [23]
and potentiation of apoptosis [24]. Consequently, epi-
thelial cells, macrophages and fibroblasts are absent or
diminished in number. However, we have been able to
demonstrate differential gene expression in the bron-
chus compared to the parenchyma in COPD patients
[14]. Thus, future studies should also include samples
from the bronchial airway to complement the present
study. Sixth, there are other cell types that maybe
potential sources of these biomarkers, including dendritic
or endovascular cells. The present study should be ex-
panded to include other cell types to more comprehen-
sively represent the true scenario. Finally, we did not
measure serum protein concentrations of these bio-
markers to test whether gene expression translates to
the serum, which would provide a necessary link to sys-
temic inflammation.
The role of these cell types in the pathogenesis of
COPD has previously been studied, and the differential
expression patterns in fibroblasts and epithelial cells
compared to macrophages merits comment. Our results
seem to suggest that epithelial cells and fibroblasts play
a major role in inflammatory gene expression in COPD.
Bronchial biopsy studies have identified epithelial cells
as components of inflammation [25]. Moreover, this
relationship is associated with smoking intensity [26].
The predominance of synthesis in epithelial cells of COPD
patients could be a consequence of remodeling that occurs
in the lung tissue of patients with COPD [27]. In this
regard, one potential mechanism contributing to airway
fibrosis is the transition of airway epithelial cells to a
mesenchymal phenotype expressing myofibroblast charac-
teristics and capable to migrate into the lamina propria.
Such a process has been termed epithelial mesenchymal
transition (EMT) [28]. When this phenomenon is accom-
panied by angiogenesis, it can explain the increased risk of
malignant transformation predominantly observed in the
large airways of COPD patients [29]. The potential role
played by EMT in the pathogenesis of COPD is currently
a very active area of research [30]. Although this study
was not specifically focused on this issue, we believe
that it may contribute to the ongoing scientific debate
in the field.
Fibroblasts are principally responsible for the production
and maintenance of the lung extracellular matrix [31].
These cells are involved in the pathogenesis of COPD,
particularly in the small bronchial airway, and their
peribronchiolar proliferation has been described as the
most limiting factor in the pathogenesis of chronic airflow
obstruction [32]. Furthermore, alterations in the func-
tional capacity of these fibroblasts can play a role in the
pathogenesis of pulmonary emphysema, which results in a
breakdown of the tissue.Conversely, gene expression in macrophages has the
reverse pattern. Macrophages play a very important role
in the pathogenesis of COPD [33]. They are central to
coordinating immunity against inhaled particles dissolved
in smoke due to their role as first-line, innate defenders
against chronic noxious stimuli in the airway and lung
parenchyma. However, their role in the synthesis of these
biomarkers is decreased. One explanation might be that
they are dedicated to other inflammatory functions in the
context of COPD.
The differences found in our study did not appreciably
change after adjusting for potential confounders, includ-
ing body mass index, age, gender, FEV1 and the Charlson
index. Although these variables have been associated
with the systemic inflammatory load [34,35], few data
are available on their relationships with local inflammatory
biomarkers in respiratory tissues. In the present study, we
failed to identify such an association. However, the current
results should be taken with caution because the sample
size may be too small for assessing the potential impact of
such variables. Future studies may utilize the information
provided in this study for determining an adequate sample
size to investigate such associations. Moreover, further
research is needed to assess the potential relationships
of potential confounders with respiratory biomarkers
obtained using non-invasive methods [36].
Although in this study we did not specifically measure
the systemic inflammatory load of the study participants,
one of the most obvious explanations for the presence of
systemic inflammation in COPD is that local inflammatory
processes occurring in the lung may cause a “spills over”
of proinflammatory molecules into the systemic circula-
tion [12]. However, the results of previous studies do not
completely support this hypothesis because of the lack of
association between airway cytokine concentrations and
the corresponding systemic levels [37]. Even though a
correlation between serum and tissue expression should
be obtained to support the “spill over” hypothesis, mRNA
quantification cannot provide reliable information as to
whether: a) the mRNA will be translated into a protein,
b) a functional protein will be translated and c) if such
a protein will be finally released into the circulation
[38]. It is also noteworthy that mRNA and protein concen-
trations do not always correlate [39]. Further functional
studies are needed to understand the complex relation-
ships between local and systemic inflammation in COPD
patients.
Conclusions
The present study provides novel data regarding the ex-
pression of CRP and SAA genes in the lung parenchyma
and indicates which cell types are primarily responsible
for gene expression of CRP and SAA. The study also
uncovers differences in production according to cell type
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the present study advance the field’s understanding of
COPD pathogenesis and the role of systemic inflammation.
Future studies should advance our understanding of gene
expression in other cell types and the relationship between
gene expression and the final serum concentrations of
these proteins.
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